Pulse Biosciences, Inc.
Pulse Biosciences, Inc. (PLSE) Financial Performance & Income Statement Overview
Analyze Pulse Biosciences, Inc. (PLSE) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Pulse Biosciences, Inc. (PLSE) Income Statement & Financial Overview
View the income breakdown for Pulse Biosciences, Inc. PLSE across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $832000.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $832000.00 | $267000.00 | $266000.00 | $299000.00 |
| Gross Profit | $0.00 | -$267000.00 | -$266000.00 | -$299000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $10.66M | $7.70M | $7.23M | $6.74M |
| SG&A Expenses | $10.16M | $5.95M | $4.23M | $3.58M |
| Operating Expenses | $20.26M | $13.65M | $11.46M | $10.32M |
| Total Costs & Expenses | $21.66M | $13.65M | $11.73M | $10.62M |
| Interest Income | $0.00 | $975000.00 | $343000.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $478000.00 |
| Depreciation & Amortization | $287000.00 | $294000.00 | $266000.00 | $299000.00 |
| EBITDA | -$19.97M | -$13.36M | -$11.43M | -$10.32M |
| EBITDA Ratio | -$24.007 | |||
| Operating Income | -$20.26M | -$13.65M | -$11.73M | -$10.62M |
| Operating Income Ratio | -$24.35 | |||
| Other Income/Expenses (Net) | $876000.00 | $975000.00 | $343000.00 | $478000.00 |
| Income Before Tax | -$19.39M | -$12.68M | -$11.38M | -$10.14M |
| Income Before Tax Ratio | -$23.30 | |||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $255724.00 |
| Net Income | -$19.39M | -$12.68M | -$11.38M | -$10.14M |
| Net Income Ratio | -$23.30 | |||
| EPS | -$0.32 | -$0.21 | -$0.20 | -$0.18 |
| Diluted EPS | -$0.32 | -$0.21 | -$0.20 | -$0.18 |
| Weighted Avg Shares Outstanding | $58.40M | $61.07M | $57.18M | $55.17M |
| Weighted Avg Shares Outstanding (Diluted) | $58.40M | $61.07M | $57.18M | $55.17M |
Over the last four quarters, Pulse Biosciences, Inc. achieved steady financial progress, growing revenue from $0.00 in Q1 2024 to $832000.00 in Q4 2024. Gross profit stayed firm with margins at N/A in Q4 2024 versus N/A in Q1 2024. Operating income totaled -$20.26M in Q4 2024, maintaining a -2435% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$19.97M. Net income dropped to -$19.39M, with EPS at -$0.32. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan